• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球卫生技术撤资:计划概述及可能的决定因素。

HEALTH TECHNOLOGY DISINVESTMENT WORLDWIDE: OVERVIEW OF PROGRAMS AND POSSIBLE DETERMINANTS.

机构信息

Health Planning Service,Regional Health Authority of Umbria,Department of

Catholic University of the Sacred Heart,Institute of Public Health.

出版信息

Int J Technol Assess Health Care. 2017 Jan;33(2):239-250. doi: 10.1017/S0266462317000514. Epub 2017 Jul 3.

DOI:10.1017/S0266462317000514
PMID:28669355
Abstract

OBJECTIVES

In the past decade, there has been a growing interest in health technology disinvestment. A disinvestment process should involve all relevant stakeholders to identify and deliver the most effective, safe, and cost-effective healthcare interventions. The aim of the present study was to describe the state of the art of health technology disinvestment around the world and to identify parameters that could be associated with the implementation of disinvestment programs.

METHODS

A systematic review of the literature was performed from database inception to November 2014, together with the collection of original data on socio-economic indicators from forty countries.

RESULTS

Overall, 1,456 records (1,199 from electronic databases and 257 from other sources) were initially retrieved. After analyzing 172 full text articles, 38 papers describing fifteen disinvestment programs/experiences in eight countries were included. The majority (12/15) of disinvestment programs began after 2006. As expected, these programs were more common in developed countries, 63 percent of which had a Beveridge model healthcare system. The univariate analysis showed that countries with disinvestment programs had a significantly higher level of Human Development Index, Gross Domestic Product per capita, public expenditure on health and social services, life expectancy at birth and a lower level of infant mortality rate, and of perceived corruption. The existence of HTA agencies in the country was a strong predictor (p = .034) for the development of disinvestment programs.

CONCLUSIONS

The most significant variables in the univariate analysis were connected by a common factor, potentially related to the overall development stage of the country.

摘要

目的

在过去十年中,人们对医疗技术撤资越来越感兴趣。撤资过程应涉及所有相关利益攸关方,以确定并提供最有效、安全和具有成本效益的医疗干预措施。本研究的目的是描述全球范围内医疗技术撤资的现状,并确定可能与撤资计划实施相关的参数。

方法

从数据库建立到 2014 年 11 月,对文献进行了系统回顾,并从 40 个国家收集了社会经济指标的原始数据。

结果

总共检索到 1456 条记录(1199 条来自电子数据库,257 条来自其他来源)。在分析了 172 篇全文文章后,纳入了 38 篇描述 8 个国家 15 个撤资计划/经验的论文。大多数(15 个中的 12 个)撤资计划是在 2006 年后开始的。正如预期的那样,这些计划在发达国家更为常见,其中 63%的国家实行贝弗里奇模式的医疗保健系统。单变量分析显示,实施撤资计划的国家人类发展指数、人均国内生产总值、公共卫生和社会服务支出、出生时预期寿命以及婴儿死亡率都显著较高,而感知到的腐败程度较低。国家是否存在 HTA 机构是发展撤资计划的一个强有力预测因素(p =.034)。

结论

单变量分析中最重要的变量由一个共同因素联系在一起,这个因素可能与国家的整体发展阶段有关。

相似文献

1
HEALTH TECHNOLOGY DISINVESTMENT WORLDWIDE: OVERVIEW OF PROGRAMS AND POSSIBLE DETERMINANTS.全球卫生技术撤资:计划概述及可能的决定因素。
Int J Technol Assess Health Care. 2017 Jan;33(2):239-250. doi: 10.1017/S0266462317000514. Epub 2017 Jul 3.
2
Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.医疗保健领域的撤资:欧洲层面卫生技术评估机构及组织活动概述
BMC Health Serv Res. 2018 Mar 1;18(1):148. doi: 10.1186/s12913-018-2941-0.
3
Disinvestment in healthcare: a scoping review of systematic reviews.医疗保健领域的撤资:系统评价的范围综述。
Int J Technol Assess Health Care. 2022 Jul 20;38(1):e69. doi: 10.1017/S0266462322000514.
4
A systematic review on current status of health technology reassessment: insights for South Korea.关于健康技术再评估现状的系统评价:对韩国的启示
Health Res Policy Syst. 2016 Nov 11;14(1):82. doi: 10.1186/s12961-016-0152-x.
5
STATUS OF DISINVESTMENT INITIATIVES IN LATIN AMERICA: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW AND A QUESTIONNAIRE.拉丁美洲撤资倡议现状:系统文献回顾和问卷调查的结果。
Int J Technol Assess Health Care. 2017 Jan;33(6):674-680. doi: 10.1017/S0266462317000812. Epub 2017 Sep 28.
6
Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.阐明医疗保健领域撤资和资源配置决策过程的案例研究:系统评价。
Int J Technol Assess Health Care. 2013 Apr;29(2):174-84. doi: 10.1017/S0266462313000068. Epub 2013 Mar 20.
7
Disinvestment Activities and Candidates in the Health Technology Assessment Community: An Online Survey.卫生技术评估界的撤资活动和候选人:一项在线调查。
Int J Technol Assess Health Care. 2019 Jan;35(3):189-194. doi: 10.1017/S0266462319000229. Epub 2019 Apr 22.
8
DRUG DISINVESTMENT FRAMEWORKS: COMPONENTS, CHALLENGES, AND SOLUTIONS.药物停用框架:组成部分、挑战与解决方案。
Int J Technol Assess Health Care. 2017 Jan;33(2):261-269. doi: 10.1017/S0266462317000277. Epub 2017 Jul 13.
9
Processes, contexts, and rationale for disinvestment: a protocol for a critical interpretive synthesis.撤资的过程、背景及基本原理:一项批判性诠释性综述方案
Syst Rev. 2014 Dec 11;3:143. doi: 10.1186/2046-4053-3-143.
10
Health technology reassessment of non-drug technologies: current practices.非药物技术的卫生技术重新评估:当前实践。
Int J Technol Assess Health Care. 2012 Jul;28(3):220-7. doi: 10.1017/S0266462312000438.

引用本文的文献

1
Disinvestment initiatives in Malaysia healthcare system: the journey from possibility to reality.马来西亚医疗保健系统中的撤资举措:从可能性到现实的历程。
GMS Health Innov Technol. 2024 Nov 19;18:Doc03. doi: 10.3205/hta000140. eCollection 2024.
2
Too Much, Too Mild, Too Early: Diagnosing the Excessive Expansion of Diagnoses.过度、过轻、过早:诊断的过度扩张之诊断
Int J Gen Med. 2022 Aug 6;15:6441-6450. doi: 10.2147/IJGM.S368541. eCollection 2022.
3
Health technology reassessment in the Brazilian public health system: Analysis of the current status.巴西公共卫生系统中的卫生技术再评估:现状分析。
PLoS One. 2019 Jul 29;14(7):e0220131. doi: 10.1371/journal.pone.0220131. eCollection 2019.
4
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.巴西对用于治疗复发缓解型多发性硬化症的肌内干扰素β的去投资评估。
Pharmacoeconomics. 2018 Feb;36(2):161-173. doi: 10.1007/s40273-017-0579-0.